Tandem Diabetes Care Inc. Common Stock (TNDM)
Stock · NASDAQ · Health Care
$16.24as of 10/16/2026
Price chart
Active signals
TNDM Signal Track Record
How signals performed across all stocks →What TNDM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -2.0% | 41% | September 14, 2026 |
| Bollinger Band Breakdown | 23 | -3.3% | 48% | September 4, 2026 |
| Bollinger Band Breakout | 19 | +1.0% | 53% | August 7, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -11.8% | 44% | September 4, 2026 |
| Any 20-session window (baseline) | -2.7% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TNDM
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that co…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 2,500
- Website
- www.tandemdiabetes.com/
Fundamentals
- 1-day range
- $16.14$17.25
- Market cap
- $1.29B
- P/E (trailing)
- —
- P/E (forward)
- 102.16
- EPS (trailing)
- $-0.93
- Dividend yield
- —
- Beta
- 1.62
- Avg. volume
- 2.06M
- Dividend pay date
- October 10, 2017
How Tandem Diabetes Care Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
21 analyst ratings
Tandem Diabetes Care Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TNDMTandem Diabetes Care Inc. Common Stock$16.24▼ 1.69%Market cap $1.29BP/E —$12.26$29.65
- AORTArtivion Inc. Common Stock$21.78▼ 0.41%Market cap $1.29BP/E 117.64$19.16$48.25
- IARTIntegra LifeSciences Holdings Corporation Common Stock$13.21▼ 2.37%Market cap $1.33BP/E —$8.7$20.49
- BVSBioventus Inc. Class A Common Stock$13.3▼ 3.69%Market cap $1.17BP/E 21.32$6.46$15.89
- IRMDiRadimed Corporation Common Stock$88.27▼ 1.23%Market cap $1.17BP/E 49.82$71.34$107.9
- ATECAlphatec Holdings Inc. Common Stock$10.46▼ 4.30%Market cap $1.42BP/E —$6.82$23.29
- DRTSAlpha Tau Medical Ltd. Ordinary Shares$12.29▼ 6.61%Market cap $1.14BP/E —$3.43$15.79
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care Inc. Common Stock | $1.29B | — | $16.24 | ▼ 1.69% | $12.26$29.65 |
| AORT Artivion Inc. Common Stock | $1.29B | 117.64 | $21.78 | ▼ 0.41% | $19.16$48.25 |
| IART Integra LifeSciences Holdings Corporation Common Stock | $1.33B | — | $13.21 | ▼ 2.37% | $8.7$20.49 |
| BVS Bioventus Inc. Class A Common Stock | $1.17B | 21.32 | $13.3 | ▼ 3.69% | $6.46$15.89 |
| IRMD iRadimed Corporation Common Stock | $1.17B | 49.82 | $88.27 | ▼ 1.23% | $71.34$107.9 |
| ATEC Alphatec Holdings Inc. Common Stock | $1.42B | — | $10.46 | ▼ 4.30% | $6.82$23.29 |
| DRTS Alpha Tau Medical Ltd. Ordinary Shares | $1.14B | — | $12.29 | ▼ 6.61% | $3.43$15.79 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Tandem Diabetes Care Q2 2026 Earnings Call Transcriptbenzinga · 10/12/2026
- Is it the Right Time to Hold TNDM Stock in Your Portfolio?Yahoo · 10/9/2026
- Intel downgraded, Marvell upgraded: Wall Street's top analyst callsYahoo · 10/7/2026
- Barclays Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $18Benzinga · 10/7/2026
- Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026Yahoo · 10/1/2026
- Tandem Diabetes Care (TNDM) Is Up 7.2% After International Launch Of Mobi Insulin Pump SystemYahoo · 10/1/2026
- Q2 Earnings Highlights: Tandem Diabetes (NASDAQ:TNDM) Vs The Rest Of The Healthcare Technology StocksYahoo · 9/30/2026
- Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20Benzinga · 9/30/2026
- Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International MarketsYahoo · 9/28/2026
Insider Activity
Insider Actions →- Morrison Susan · August 15, 2026 · Tax Withholding314 @ $22.72
- Kyrillos Jean-Claude · August 15, 2026 · Option Exercise1.0K
- Gasser Elizabeth Anne · August 15, 2026 · Option Exercise1.9K
- Gasser Elizabeth Anne · August 15, 2026 · Option Exercise1.1K
- Gasser Elizabeth Anne · August 15, 2026 · Tax Withholding1.0K @ $22.72
- Gasser Elizabeth Anne · August 15, 2026 · Tax Withholding589 @ $22.72
- Carpenter Rick · August 15, 2026 · Option Exercise1.6K
- Carpenter Rick · August 15, 2026 · Option Exercise897
- Carpenter Rick · August 15, 2026 · Tax Withholding820 @ $22.72
- Carpenter Rick · August 15, 2026 · Tax Withholding457 @ $22.72
- Hansen Shannon Marie · August 15, 2026 · Option Exercise1.9K
- Hansen Shannon Marie · August 15, 2026 · Option Exercise1.1K
- Hansen Shannon Marie · August 15, 2026 · Tax Withholding976 @ $22.72
- Hansen Shannon Marie · August 15, 2026 · Tax Withholding559 @ $22.72
- Sheridan John F · August 15, 2026 · Option Exercise9.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 78.90M
- Total value held
- $1.45B
- Institutional holders
- 266
- Unknown10.69M
- Unknown7.23M
- Unknown4.73M
- Unknown3.10M
- Unknown3.04M
- Unknown2.69M
- Unknown2.66M
- Unknown2.30M
- Unknown2.28M
- Unknown2.22M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating
Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating. Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.